Objectives: The epidemiology of invasive Haemophilus influenzae has changed in recent years. b-Lactamasenegative ampicillin-resistant (BLNAR) invasive isolates have recently been described in Europe but their clinical significance is unclear. Our main goal was to determine whether invasive H. influenzae remains susceptible to b-lactam antibiotics indicated in the treatment of invasive infections.
Introduction
In the past, Haemophilus influenzae type b (Hib) was a major cause of invasive infections, especially in children ,5 years of age;
1 -3 however, after widespread vaccination against Hib, nontypeable H. influenzae has become predominant among invasive H. influenzae. 4 -6 Invasive infections due to H. influenzae are usually treated with b-lactam antibiotics including aminopenicillins or cephalosporins. Aminopenicillin resistance in H. influenzae is well documented and may be mediated by b-lactamase production or by alterations in the transpeptidase domain of penicillin-binding proteins (PBPs).
Interestingly, b-lactamase-negative ampicillin-resistant (BLNAR) isolates with PBP3 modifications can show decreased susceptibility to both aminopenicillins and cephalosporins. 7 -9 Some authors 10, 11 have recently described invasive infections caused by BLNAR H. influenzae in Europe.
The main objective of this study was to determine whether invasive isolates of H. influenzae in Spain remain susceptible to the b-lactam antibiotics indicated in the treatment of invasive infections, such as amoxicillin/clavulanic acid and third-generation cephalosporins. The specific objectives of the study were: (i) to determine the susceptibility of invasive H. influenzae to b-lactam antibiotics according to EUCASTand CLSI (formerly NCCLS) criteria;
# The Author 2013. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com J Antimicrob Chemother 2014; 69: 111 -116 doi:10.1093/jac/dkt324 Advance Access publication 13 August 2013 (ii) to describe the molecular mechanisms and molecular epidemiology of aminopenicillin-resistant invasive H. influenzae, with a special emphasis on BLNAR isolates; and (iii) to determine the in vitro bactericidal activity of amoxicillin and cefotaxime for isolates of the BLNAR genotype (gBLNAR) with decreased susceptibility to aminopenicillins and cephalosporins.
Materials and methods

Study isolates
The Centro Nacional de Microbiología is a public health and research institution that runs an active national surveillance programme for invasive Haemophilus influenzae infections in Spain. We studied 307 clinical isolates of H. influenzae causing individual invasive infections (265 from blood and 42 from CSF) submitted to the Spanish Haemophilus reference laboratory from 70 different hospitals in 30 Spanish geographical regions from 1 January 2004 to 31 October 2009. A total of 183 isolates were from adults (59.6%) and 51 from children (16.6%); for 73 (23.8%) isolates, the age of the patient was unknown. Of the 307 isolates, 67 (21.8%) were submitted from consecutive infected patients attending the Gregorio Marañó n University Hospital (GMUH), one of the largest hospitals in Spain and covering a large administrative health area.
Haemophilus isolates were identified according to standard microbiological methods, including sequencing of 16S RNA when needed, and molecular methods were used to determine the presence of capsular genes. 12 
Susceptibility testing
Antibiotic susceptibility was determined by the broth microdilution method on Haemophilus test medium using microtitre plates (Sensititre Emiza 14, Trek Diagnostics Inc. Westlake, OH, USA) 8 according to the CLSI guidelines. 13 Susceptibility data were interpreted by CLSI and EUCAST clinical breakpoints.
14, 15 The following antibiotics were studied: ampicillin, amoxicillin, amoxicillin/clavulanic acid (2: 1 ratio), cefuroxime, cefotaxime, cefixime and imipenem.
b-Lactamase production was determined by the chromogenic cephalosporin test with nitrocefin as substrate. 16 H. influenzae ATCC 49247 and ATCC 49766 were used as quality control strains as recommended. 13 
Genotype definition
Invasive isolates were classified into four different genotypes as follows: gBLNAS, b-lactamase-negative isolates that were ampicillin susceptible and lacked detectable mechanisms of resistance to b-lactams; gBLNAR, b-lactamase-negative isolates with PBP3 amino acid substitutions causing reduced susceptibility to ampicillin (defined by either an Asn526Lys or an Arg517His substitution); gBLPAR, b-lactamase-positive isolates that were ampicillin resistant without gBLNAR-defining PBP3 amino acid substitutions; and gBLPACR, b-lactamase-positive isolates also presenting PBP3 amino acid substitutions.
17 gBLNAR isolates were classified into different PBP3 mutation patterns as previously described. 7, 18 PCR and DNA sequencing Amplification of the PBP3 transpeptidase domain of the ftsI gene from amino acid positions 327 to 540 was carried out as previously described 9 in a total of 162 (52.8%) isolates selected as described below.
b-Lactamase-negative isolates
Of the 255 invasive isolates that were b-lactamase negative, ftsI was sequenced in 110 (43.1%), comprising 47 with an amoxicillin MIC ≤0.5 mg/L (possible susceptible control group or gBLNAS) 8 and all 63
isolates with an amoxicillin MIC ≥1 mg/L (a group that according to our previous data was suggestive of being gBLNAR). 8 b-Lactamase-positive isolates ftsI was sequenced in all 52 b-lactamase positive isolates; 42 had an amoxicillin/clavulanic acid MIC ,2 mg/L, suggesting that they were gBLPAR, 8 and 10 had an amoxicillin/clavulanic acid MIC ≥2 mg/L, suggesting that they were gBLPACR. 8 The presence of bla TEM , its promoter region and the bla ROB gene was studied in all b-lactamase-positive isolates, as previously described.
7,9
Molecular epidemiology
To elucidate whether invasive gBLNAR isolates from different geographical regions were epidemiologically linked, we analysed them by PFGE and multilocus sequence typing (MLST).
PFGE was carried out on 95 selected isolates as previously described; 18 40 of these were capsulated (29 fully susceptible to aminopenicillins, 7 gBLPAR, 2 gBLPACR and 2 gBLNAR) and 55 were non-typeable and gBLNAR. A genetic similarity dendrogram was obtained according to the Dice correlation coefficient with a tolerance level of 1% (InfoQuest FP software version 4.5; Bio-Rad, USA).
MLST was carried out on a selected sample of 41 isolates (23 capsulated and 18 non-typeable and gBLNAR) representing specific PFGE profiles; internal fragments of the seven housekeeping genes were sequenced using published methods. 19, 20 The sequences obtained were submitted to the MLST website 21 for assignment of allele numbers and sequence type (ST).
Time -kill curves
Time-kill curve experiments were undertaken using two gBLNAR isolates of the III-like group, 18 one isolated in 2006 and the other in 2009, from distant geographical locations. The III-like group is characterized by Met377Ile and Ser385Thr mutations in the SSN motif 18 (Table S1 , available as Supplementary data at JAC Online) and presents reduced susceptibility to aminopenicillins and cefotaxime. 18 The in vitro bactericidal activities were determined according to CLSI-recommended methods. 22 Time-kill experiments were performed at concentrations 4×the MICs of amoxicillin and cefotaxime for the study isolates. Each time-kill experiment was carried out in triplicate in separate experiments. A decrease of 3 log 10 cfu/mL in bacterial counts in antimicrobial solution compared with counts for the growth control was considered bactericidal. 22 
Statistical analysis
Differences in the prevalence of mechanisms of resistance and antibiotic susceptibility data were assessed by the x 2 test. A P value of 0.05 was considered statistically significant.
Results and discussion
Clinical isolates and antibiotic susceptibility
Characteristics of the invasive isolates
Of the 307 invasive isolates, 266 (86.6%) were non-typeable (62% adults, 15.4% children and 22.6% unknown) and 41 (13.4%) were capsulated [17 (6%) type f, 15 (5%) type b, 6 (2%) type e and 3 (1%) type a]. Of the 41 capsulated isolates, there were 21 from adults (nine type b, four type e and eight type f), 10 from children (five type b, three type f and two type a) and 10 from patients of unknown age. Of the 42 CSF isolates, 37 were non-typeable and 5 were capsulated (three type f, one type b and one type a).
Antibiotic susceptibility
Of the 307 invasive isolates studied, 52 (16.9%) produced b-lactamase (16.4% of isolates from the GMUH and 17% from the remaining participant hospitals; P¼ 1).
The total rate of ampicillin resistance was 19.2% using EUCAST breakpoints and 16.9% using those of the CLSI (Table 1) . The rates of resistance to amoxicillin/clavulanic acid were 1.3% (EUCAST) and 0% (CLSI); by the EUCAST criteria, two of nine gBLPACR isolates (22.2%) were resistant to amoxicillin/clavulanic acid. In addition, 99.3% (EUCAST) and 100% (CLSI) of the isolates were susceptible to cefotaxime and cefixime, respectively (Table 1 ). All isolates were susceptible to imipenem by EUCAST and CLSI breakpoints ( Table 1) .
The most important discrepancies detected between the EUCAST and CLSI criteria were for cefuroxime; by current CLSI criteria, 99.7% of the invasive isolates were susceptible to cefuroxime and one gBLNAR isolate was intermediate. EUCAST has two different breakpoints for cefuroxime, intravenous and oral; according to No differences in the antibiotic susceptibility rates were found between the consecutive invasive isolates submitted by the GMUH and the remaining isolates submitted by the other participants.
Mechanisms of resistance to aminopenicillins
MICs in relation to resistance mechanisms
Known mechanisms of resistance were found in the majority of isolates with an amoxicillin/clavulanic acid MIC ≥1 mg/L, including all isolates with MICs of 2 -4 mg/L, which were essentially gBLNAR. All isolates with cefuroxime MICS of 4 -8 mg/L, considered resistant by current EUCAST breakpoints but susceptible or intermediate by CLSI, were also gBLNAR. In addition, most isolates with a cefuroxime MIC of 2 mg/L also had identifiable resistance mechanisms, and were mostly gBLNAR and to a lesser extent gBLPAR. Approximately 10% of the isolates with a cefuroxime MIC of 1 mg/L also were gBLNAR (data not shown).
The vast majority of the study isolates had cefotaxime MICs ≤0.06 mg/L; only two isolates (0.7%) had an MIC of 0.25 mg/L for this antibiotic (both from the III-like group 18 ) (Table S1 , available as Supplementary data at JAC Online) and were considered to be susceptible by CLSI or resistant by EUCAST. This III-like group is described here for the first time in invasive isolates in Europe.
There were 192 isolates with an amoxicillin MIC ≤0.5 mg/L, of which 47 were analysed by sequencing the ftsI gene; 43 of the 47 (91.48%) were identified as gBLNAS. Of the 63 isolates with an amoxicillin MIC ≥1 mg/L, 54 (85.7%) were identified as gBLNAR. In addition, of the 42 b-lactamase-positive isolates with an amoxicillin/clavulanic acid MIC ,2 mg/L, 39 (92.9%) were identified as gBLPAR, and of the 10 isolates with an amoxicillin/clavulanic acid MIC ≥2 mg/L, 6 (60%) were identified as gBLPACR.
Overall, 197 (64.2%) of the 307 invasive isolates were ampicillinsusceptible (BLNAS), 52 (26.4%) of which were confirmed by ftsI sequencing (gBLNAS). Sixty-eight (22.15%) of the 307 isolates had PBP3 mutations, of which 59 were gBLNAR (19.2%) and 9 were gBLPACR (2.9%). Finally, 43 of the 307 isolates were gBLPAR (14%). The percentage of isolates with PBP3 mutations found in this study is among the highest published 10, 11 and the gBLNAR mechanism was the most prevalent in this study (19.2%), exceeding the proportion of isolates that produced b-lactamase (16.9%).
Capsule production and mechanisms of resistance
Capsulate isolates produced b-lactamase more frequently than did non-typeable isolates (24.5% versus 15.8%). In contrast, PBP3 mutations were less frequent in capsulate isolates than in non-typeable isolates (9.8% versus 24%).
PBP3 mutation patterns and genotypes
Invasive gBLNAR isolates belonged to the following groups: 42.4% to group IIc, 37.3% to group IIb, 13.6% to group IIa and 3.4% each to groups I and III-like (the two group III-like isolates had MICs of cefotaxime and cefixime of 0.25 and 0.5 mg/L, respectively). Of the gBLPACR isolates, 7 (77.8%) were group IIb and 2 (22.2%) were group IIc (Table S1 , available as Supplementary data at JAC Online).
The frequencies of these gBLNAR groups are similar to those previously described by us for respiratory isolates. 18 In Sweden, the most frequent group previously found in invasive isolates was shown to be IIb, 11 which is also one of the most common groups in this study.
b-Lactamase production
All b-lactamase-positive isolates were of the TEM-1 type (n¼ 52, 16.9%) with the following promoters: 33 were Pdel (63.5%), 10 were Prpt (19.2%), 8 were PaPb (15.4%), and 1 was 2Prpt (1.9%). The Pdel promoter was also found to be predominant in Sweden, although the authors named it bla TEM-1 -PD. 11 
Molecular epidemiology
PFGE profiles
All 41 capsulate strains studied by PFGE, regardless of the resistance mechanism, were grouped into five large PFGE clusters corresponding to isolates of type a, type b, type e and two type f profiles (data not shown).
In contrast, the 55 non-typeable gBLNAR isolates studied were grouped into 38 PFGE profiles, 28 of which were composed of single unique isolates and 10 of which had two to four isolates ( Figure S1 , available as Supplementary data at JAC Online). In general, the 10 gBLNAR clusters were constituted by isolates originating from different geographical areas ( Figure S1 , available as Supplementary data at JAC Online).
MLST profiles
MLST was determined in 23 capsulate strains (11 type f, 11 type b and 1 type e). Type b isolates belonged to three different STs (6, 190 and 662) , and type f isolates to seven STs (106, 124, 973, 1124, 1125, 1126 and 1127), four of which are first described in this study (1124, 1125, 1126 and 1127) ; the type e isolate was ST18.
MLST was also carried out in 18 gBLNAR non-typeable isolates selected on the basis of previous PFGE profiles; they comprised 15 different STs (107, 140, 155, 201, 367, 949, 1113, 1114, 1115, 1117, 1118, 1120, 1121, 1122, 1123), nine of which are first described in this study (1113, 1114, 1115, 1117, 1118, 1120, 1121, 1122, 1123) . The majority of STs obtained from isolates belonging to the same PFGE cluster were either single-locus or double-locus variants ( Figure S1 , available as Supplementary data at JAC Online). As seen in another study, the majority of BLNAR non-typeable isolates had different ST profiles. 11 According to PFGE and MLST data, only one cluster of four gBLNAR isolates was identified, all of which had the same PBP3 mutations (IIc group). Each of these came from distant geographical areas and belonged to STs 949 (two isolates), 1122 (a doublelocus variant of ST 949) and 1123 (a single-locus variant of ST 949) ( Figure S1 , available as Supplementary data at JAC Online).
Time -kill curves
The bactericidal activities of amoxicillin (4×MIC) and cefotaxime (4×MIC) were determined in two individual gBLNAR III-like isolates (Figure 1a) . Amoxicillin was bactericidal after the first 2 h of García-Cobos et al.
incubation for both gBLNAR isolates, and cefotaxime was bactericidal after 4 h for the same two isolates (Figure 1b) . In summary, we have shown in this study that the gBLNAR mechanism of antibiotic resistance was the most common found in invasive infections caused by H. influenzae in Spain, followed by b-lactamase production. gBLNAR isolates were genetically very diverse and showed very little clonal spread. The vast majority of invasive isolates, regardless of their mechanism of resistance to b-lactam antibiotics, were susceptible to amoxicillin/clavulanic acid, cefotaxime, cefixime and imipenem, both by EUCAST and CLSI clinical breakpoints In addition, kill-curve experiments demonstrated that amoxicillin and cefotaxime were bactericidal against two gBLNAR isolates with decreased susceptibility to aminopenicillins and third-generation cephalosporins. However, the MICs of b-lactam for our gBLNAR invasive isolates were generally low; precaution is advised when treating this kind of pathogen with b-lactam antibiotics. b-Lactam resistance in invasive H. influenzae in Spain
